The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cyclin D1 Expression Mediated by Phosphatidylinositol 3-Kinase through mTOR-p70S6K-Independent Signaling in Growth Factor-Stimulated NIH 3T3 Fibroblasts
Open accessAbstract
Phosphatidylinositol (PI) 3-kinase is required for G1 to S phase cell cycle progression stimulated by a variety of growth factors and is implicated in the activation of several downstream effectors, including p70(S6K). However, the molecular mechanisms by which PI 3-kinase is engaged in activation of the cell cycle machinery are not well understood. Here we report that the expression of a dominant negative (DN) form of either the p110alpha catalytic or the p85 regulatory subunit of heterodimeric PI 3-kinase strongly inhibited epidermal growth factor (EGF)-induced upregulation of cyclin D1 protein in NIH 3T3(M17) fibroblasts. The PI 3-kinase inhibitors LY294002 and wortmannin completely abrogated increases in both mRNA and protein levels of cyclin D1 and phosphorylation of pRb, inducing G1 arrest in EGF-stimulated cells. By contrast, rapamycin, which potently suppressed p70(S6K) activity throughout the G1 phase, had little inhibitory effect, if any, on either of these events. PI 3-kinase, but not rapamycin-sensitive pathways, was also indispensable for upregulation of cyclin D1 mRNA and protein by other mitogens in NIH 3T3 (M17) cells and in wild-type NIH 3T3 cells as well. We also found that an enforced expression of wild-type p110 was sufficient to induce cyclin D1 protein expression in growth factor-deprived NIH 3T3(M17) cells. The p110 induction of cyclin D1 in quiescent cells was strongly inhibited by coexpression of either of the PI 3-kinase DN forms, and by LY294002, but was independent of the Ras-MEK-ERK pathway. Unlike mitogen stimulation, the p110 induction of cyclin D1 was sensitive to rapamycin. These results indicate that the catalytic activity of PI 3-kinase is necessary, and could also be sufficient, for upregulation of cyclin D1, with mTOR signaling being differentially required depending upon cellular conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Phosphatidylinositol-3-OH kinase direct target of Ras
Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954
Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k
Jefferies, H. B. J., Fumagalli, S., Dennis, P. B., Reinhard, C., Pearson, R. B., & Thomas, G. (1997) · The EMBO Journal · doi:10.1093/emboj/16.12.3693 · Cited by 934
Phosphorylation and Activation of p70 s6k by PDK1
Pullen, N., Dennis, P. B., Andjelkovic, M., Dufner, A., Kozma, S. C., Hemmings, B. A., & Thomas, G. (1998) · Science · doi:10.1126/science.279.5351.707 · Cited by 826
TOR signalling and control of cell growth
Thomas, G., & Hall, M. N. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80078-6 · Cited by 462 · cited 2×
“Thus, rapamycin blocks p70 activation in response to diverse mitogenic stimuli (13, 56, 58, 69).”
Background
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Synthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., & Waterfield, M. D. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.615 · Cited by 1,204
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Lawlor, M. A., & Alessi, D. R. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.16.2903 · Cited by 1,071
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
mTOR-targeted therapy of cancer with rapamycin derivatives
Vignot, S., Faivre, S., Aguirre, D., & Raymond, E. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi113 · Cited by 617
Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle
Ekholm, S. V., & Reed, S. I. (2000) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00151-4 · Cited by 588
Integrins and cell proliferation
Schwartz, M. A., & Assoian, R. K. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.14.2553 · Cited by 518
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Integrating the MAP kinase signal into the G1 phase cell cycle machinery
Roovers, K., & Assoian, R. K. (2000) · BioEssays · doi:10.1002/1521-1878(200009)22:9<818::aid-bies7>3.0.co;2-6 · Cited by 458
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Humar, R., Kiefer, F. N., Berns, H., Resink, T. J., & Battegay, E. J. (2002) · The FASEB Journal · doi:10.1096/fj.01-0658com · Cited by 381
Assoian, R. K., & Schwartz, M. A. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00155-6 · Cited by 341
Okamoto, H., Takuwa, N., Yokomizo, T., Sugimoto, N., Sakurada, S., Shigematsu, H., & Takuwa, Y. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.24.9247-9261.2000 · Cited by 329
Self-citationTiming of cyclin D1 expression within G1 phase is controlled by Rho
Welsh, C. F., Roovers, K., Villanueva, J., Liu, Y., Schwartz, M. A., & Assoian, R. K. (2001) · Nature Cell Biology · doi:10.1038/ncb1101-950 · Cited by 323
Pene, F., Claessens, Y.-E., Muller, O., Viguié, F., Mayeux, P., Dreyfus, F., Lacombe, C., & Bouscary, D. (2002) · Oncogene · doi:10.1038/sj.onc.1205923 · Cited by 295
Weng, L.-P. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.6.599 · Cited by 264
Sugimoto, N., Takuwa, N., Okamoto, H., Sakurada, S., & Takuwa, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.5.1534-1545.2003 · Cited by 264
Self-citationRapamycin: an anti-cancer immunosuppressant?
Law, B. K. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.009 · Cited by 252
Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0081-9 · Cited by 90
Hecquet, C., Lefevre, G., Valtink, M., Engelmann, K., & Mascarelli, F. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0519 · Cited by 29
Metadata
- Authors
- Takuwa, N., Fukui, Y., & Takuwa, Y.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1999-02-01
- Volume
- 19
- Issue
- 2
- Pages
- 1346-1358
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2127219942
- Cited by
- 182
- References
- 6
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.